Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

Alfred K. Cheung, Tara I. Chang, William C. Cushman, Susan L. Furth, Fan Fan Hou, Joachim H. Ix, Gregory A. Knoll, Paul Muntner, Roberto Pecoits-Filho, Mark J. Sarnak, Sheldon W. Tobe, Charles R.V. Tomson, Lyubov Lytvyn, Jonathan C. Craig, David J. Tunnicliffe, Martin Howell, Marcello Tonelli, Michael Cheung, Amy Earley, Johannes F.E. Mann

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)
3 Downloads (Pure)

Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease for patients not receiving dialysis represents an update to the KDIGO 2012 guideline on this topic. Development of this guideline update followed a rigorous process of evidence review and appraisal. Guideline recommendations are based on systematic reviews of relevant studies and appraisal of the quality of the evidence. The strength of recommendations is based on the “Grading of Recommendations Assessment, Development and Evaluation” (GRADE) approach. The scope includes topics covered in the original guideline, such as optimal blood pressure targets, lifestyle interventions, antihypertensive medications, and specific management in kidney transplant recipients and children. Some aspects of general and cardiovascular health, such as lipid and smoking management, are excluded. This guideline also introduces a chapter dedicated to proper blood pressure measurement since all large randomized trials targeting blood pressure with pivotal outcomes used standardized preparation and measurement protocols adhered to by patients and clinicians. Based on previous and new evidence, in particular the Systolic Blood Pressure Intervention Trial (SPRINT) results, we propose a systolic blood pressure target of less than 120 mm Hg using standardized office reading for most people with chronic kidney disease (CKD) not receiving dialysis, the exception being children and kidney transplant recipients. The goal of this guideline is to provide clinicians and patients a useful resource with actionable recommendations supplemented with practice points. The burden of the recommendations on patients and resources, public policy implications, and limitations of the evidence are taken into consideration. Lastly, knowledge gaps and recommendations for future research are provided.

Original languageEnglish
Pages (from-to)559-569
Number of pages11
JournalKidney International
Volume99
Issue number3
DOIs
Publication statusPublished - Mar 2021

Keywords

  • albuminuria
  • ambulatory blood pressure monitoring
  • angiotensin II receptor blocker
  • angiotensin-converting enzyme inhibitor
  • antihypertensive agents
  • automated office blood pressure
  • blood pressure measurement
  • blood pressure targets
  • children
  • chronic kidney disease
  • creatinine
  • diabetes
  • dietary sodium
  • evidence-based
  • guideline
  • home blood pressure monitoring
  • hyperkalemia
  • KDIGO
  • kidney transplant recipient
  • lifestyle
  • mineralocorticoid receptor antagonist
  • office blood pressure
  • physical activity
  • potassium
  • proteinuria
  • renin-angiotensin system
  • standardized office blood pressure
  • systematic review
  • weight loss

Fingerprint

Dive into the research topics of 'Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease'. Together they form a unique fingerprint.

Cite this